157 related articles for article (PubMed ID: 36992433)
21. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
[TBL] [Abstract][Full Text] [Related]
22. Dynamics of HBV DNA levels, HBV mutations and biochemical parameters during antiviral therapy in a patient with HBeAg-negative chronic hepatitis B.
Sa-nguanmoo P; Tangkijvanich P; Payungporn S; Chieochansin T; Thawornsuk N; Chongsrisawat V; Poovorawan Y
Asian Pac J Allergy Immunol; 2007; 25(2-3):183-8. PubMed ID: 18035807
[TBL] [Abstract][Full Text] [Related]
23. The gamma-glutamyl transpeptidase-to-platelet ratio predicts liver fibrosis and cirrhosis in HBeAg-positive chronic HBV infection patients with high HBV DNA and normal or mildly elevated alanine transaminase levels in China.
Li Q; Li W; Huang Y; Chen L
J Viral Hepat; 2016 Nov; 23(11):912-919. PubMed ID: 27375134
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment.
Gil-García AI; Madejón A; Francisco-Recuero I; López-López A; Villafranca E; Romero M; García A; Olveira A; Mena R; Larrubia JR; García-Samaniego J
World J Gastroenterol; 2019 Oct; 25(38):5883-5896. PubMed ID: 31636479
[TBL] [Abstract][Full Text] [Related]
25. Clinical and virological features of chronic hepatitis B in the French national surveillance program, 2008-2012: A cross-sectional study.
Chevaliez S; Roudot-Thoraval F; Brouard C; Gordien E; Zoulim F; Brichler S; Brodard V; Pioche C; Pawlotsky JM; Leroy V;
JHEP Rep; 2022 Dec; 4(12):100593. PubMed ID: 36313185
[TBL] [Abstract][Full Text] [Related]
26. Management of chronic hepatitis B: status and challenges beyond treatment guidelines.
Wiegand J; van Bömmel F; Berg T
Semin Liver Dis; 2010 Nov; 30(4):361-77. PubMed ID: 20960376
[TBL] [Abstract][Full Text] [Related]
27. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
[TBL] [Abstract][Full Text] [Related]
28. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B.
Wong GL; Chan HL; Wong CK; Leung C; Chan CY; Ho PP; Chung VC; Chan ZC; Tse YK; Chim AM; Lau TK; Wong VW
J Hepatol; 2014 Feb; 60(2):339-45. PubMed ID: 24128413
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.
Kaneko S; Kurosaki M; Inada K; Kirino S; Hayakawa Y; Yamashita K; Osawa L; Sekiguchi S; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Itakura J; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
J Gastroenterol Hepatol; 2021 Oct; 36(10):2943-2951. PubMed ID: 34057248
[TBL] [Abstract][Full Text] [Related]
30. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease.
Mohamadnejad M; Montazeri G; Fazlollahi A; Zamani F; Nasiri J; Nobakht H; Forouzanfar MH; Abedian S; Tavangar SM; Mohamadkhani A; Ghoujeghi F; Estakhri A; Nouri N; Farzadi Z; Najjari A; Malekzadeh R
Am J Gastroenterol; 2006 Nov; 101(11):2537-45. PubMed ID: 17029616
[TBL] [Abstract][Full Text] [Related]
31. The prognosis and management of inactive HBV carriers.
Invernizzi F; Viganò M; Grossi G; Lampertico P
Liver Int; 2016 Jan; 36 Suppl 1():100-4. PubMed ID: 26725905
[TBL] [Abstract][Full Text] [Related]
32. [Chronic hepatitis B virus (HBV) infection: usefulness of the combination of HBeAg and ALT determination to predict a high HBV-DNA level and therefore the necessity of referral to a specialist for possible antiviral treatment].
Veldhuijzen IK; Mostert MC; Niesters HG; Richardus JH; de Man RA
Ned Tijdschr Geneeskd; 2008 Jun; 152(25):1426-30. PubMed ID: 18624006
[TBL] [Abstract][Full Text] [Related]
33. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
Song BC; Cho YK; Jwa H; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU
Clin Mol Hepatol; 2014 Dec; 20(4):355-60. PubMed ID: 25548741
[TBL] [Abstract][Full Text] [Related]
34. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
Cho JH; Lim JH; Park GY; Kim JS; Kang YJ; Kwon O; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD
Transpl Infect Dis; 2014 Apr; 16(2):295-303. PubMed ID: 24628837
[TBL] [Abstract][Full Text] [Related]
35. HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis B.
Yuen L; Revill PA; Rosenberg G; Wagner J; Littlejohn M; Bayliss J; Jackson K; Tan SK; Gaggar A; Kitrinos K; Subramanian M; Gane E; Chan HLY; Li X; Bowden S; Locarnini S; Thompson A
J Viral Hepat; 2020 Oct; 27(10):1061-1070. PubMed ID: 32384174
[TBL] [Abstract][Full Text] [Related]
36. HBV: Do I treat my immunotolerant patients?
Vlachogiannakos J; Papatheodoridis GV
Liver Int; 2016 Jan; 36 Suppl 1():93-9. PubMed ID: 26725904
[TBL] [Abstract][Full Text] [Related]
37. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination.
Wong GL; Chan HL; Yu Z; Chan HY; Tse CH; Wong VW
J Gastroenterol Hepatol; 2013 Dec; 28(12):1842-8. PubMed ID: 23829381
[TBL] [Abstract][Full Text] [Related]
38. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?
Papatheodoridis GV; Manesis EK; Manolakopoulos S; Elefsiniotis IS; Goulis J; Giannousis J; Bilalis A; Kafiri G; Tzourmakliotis D; Archimandritis AJ
Hepatology; 2008 Nov; 48(5):1451-9. PubMed ID: 18924246
[TBL] [Abstract][Full Text] [Related]
39. HBeAg-negative chronic hepatitis patients should be monitored more strictly: a cross-sectional retrospective study on antiviral treatment-naïve patients.
Zeng DW; Dong J; Zhang JM; Zhu YY; Jiang JJ; Liu YR
J Med Virol; 2015 Oct; 87(10):1682-8. PubMed ID: 25965250
[TBL] [Abstract][Full Text] [Related]
40. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load.
Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
Gastroenterology; 2012 May; 142(5):1140-1149.e3; quiz e13-4. PubMed ID: 22333950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
